bluebird bio Inc (BLUE) - Financial and Strategic SWOT Analysis Review

Region:North America

Author(s):

Product Code:GDPH137067FSA

Download Sample Report download
Buy the Full ReportStarting from $125
Published on

October 2018

Total pages

46

Table of Content

Download Sample Report download
Buy the Full ReportStarting from $125

About the Report

About the Report

bluebird bio Inc (BLUE)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description-A detailed description of the company's operations and business divisions.

- Corporate strategy-Analyst's summarization of the company's business strategy.

- SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

- Company history-Progression of key events associated with the company.

- Major products and services-A list of major products, services and brands of the company.

- Key competitors-A list of key competitors to the company.

- Key employees-A list of the key executives of the company.

- Executive biographies-A brief summary of the executives' employment history.

- Key operational heads-A list of personnel heading key departments/functions.

- Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

- Key manufacturing facilities-A list of key manufacturing facilities of the company.

- Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

- Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Bluebird Bio Inc (bluebird bio) is a clinical stage biotechnology company that focuses on the development of new gene therapies for the treatment of severe genetic diseases and cancer. The company develops its products based on integrated product platforms such as gene therapy, cancer immunotherapy and gene editing. Its product pipeline includes Lenti D for the treatment of cerebral adrenoleukodystrophy (CALD); LentiGlobin for the treatment of transfusion-dependent beta thalassemia and sickle cell disease, besides compounds under development for the treatment of various cancers. The company has collaboration with various pharmaceutical companies to discover, develop and commercialize gene therapy products to treat cancer. bluebird bio is headquartered in Cambridge, Massachusetts, the US.

bluebird bio Inc Key Recent Developments

Oct 05,2018: bluebird bio Announces European Medicines Agency's Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia

Oct 05,2018: bluebird bio Announces European Medicines Agency s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia

Oct 01,2018: bluebird bio to Present at the LEERINK Partners Roundtable Series Rare Disease Immuno-Oncology

Aug 24,2018: Bluebird Bio and Gritstone Oncology partner on cancer cell therapies

Aug 08,2018: Bluebird Bio and Regeneron to collaborate on cancer cell therapies

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

- The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Products

Products

bluebird bio Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Companies

Sangamo Therapeutics Inc

Juno Therapeutics Inc

Intellia Therapeutics Inc

GlycoMimetics Inc

Global Blood Therapeutics Inc

Bellicum Pharmaceuticals Inc

ApoPharma Inc

Adaptimmune LLC

Acceleron Pharma Inc

Table of Contents

Table of Contents

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Section 1-About the Company 6

bluebird bio Inc-Key Facts 6

bluebird bio Inc-Key Employees 7

bluebird bio Inc-Key Employee Biographies 8

bluebird bio Inc-Major Products and Services 10

bluebird bio Inc-History 11

bluebird bio Inc-Company Statement 13

bluebird bio Inc-Locations And Subsidiaries 14

Head Office 14

Other Locations & Subsidiaries 14

Section 2-Company Analysis 15

Company Overview 15

bluebird bio Inc-Business Description 16

bluebird bio Inc-Corporate Strategy 17

bluebird bio Inc-SWOT Analysis 18

SWOT Analysis-Overview 18

bluebird bio Inc-Strengths 18

bluebird bio Inc-Weaknesses 19

bluebird bio Inc-Opportunities 20

bluebird bio Inc-Threats 21

bluebird bio Inc-Key Competitors 22

Section 3-Company Financial Ratios 23

Financial Ratios-Capital Market Ratios 23

Financial Ratios-Annual Ratios 24

Performance Chart 26

Financial Performance 26

Financial Ratios-Interim Ratios 27

Financial Ratios-Ratio Charts 28

Section 4-Company's Lifesciences Financial Deals and Alliances 29

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

bluebird bio Inc, Recent Deals Summary 31

Section 5-Company's Recent Developments 32

Oct 05, 2018: bluebird bio Announces European Medicines Agency's Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 32

Oct 05, 2018: bluebird bio Announces European Medicines Agency's Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 33

Oct 05, 2018: bluebird bio Announces European Medicines Agency's Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 34

Oct 05, 2018: bluebird bio Announces European Medicines Agency s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 35

Oct 05, 2018: bluebird bio Announces European Medicines Agency s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 36

Oct 05, 2018: bluebird bio Announces European Medicines Agency s Acceptance of Marketing Authorization Application for LentiGlobin Gene Therapy for the Treatment of Transfusion-Dependent -Thalassemia 37

Aug 24, 2018: Bluebird Bio and Gritstone Oncology partner on cancer cell therapies 38

Aug 24, 2018: Bluebird Bio and Gritstone Oncology partner on cancer cell therapies 39

Aug 08, 2018: Bluebird Bio and Regeneron to collaborate on cancer cell therapies 40

Aug 08, 2018: Bluebird Bio and Regeneron to collaborate on cancer cell therapies 41

Section 6-Appendix 42

Methodology 42

Ratio Definitions 42

About GlobalData 46

Contact Us 46

Disclaimer 46


List of Figure

List of Figures

bluebird bio Inc, Performance Chart (2013-2017) 26

bluebird bio Inc, Ratio Charts 28

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 30


List of Table

List of Tables

bluebird bio Inc, Key Facts 6

bluebird bio Inc, Key Employees 7

bluebird bio Inc, Key Employee Biographies 8

bluebird bio Inc, Major Products and Services 10

bluebird bio Inc, History 11

bluebird bio Inc, Other Locations 14

bluebird bio Inc, Subsidiaries 14

bluebird bio Inc, Key Competitors 22

bluebird bio Inc, Ratios based on current share price 23

bluebird bio Inc, Annual Ratios 24

bluebird bio Inc, Annual Ratios (Cont...1) 25

bluebird bio Inc, Interim Ratios 27

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 29

bluebird bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018 30

bluebird bio Inc, Recent Deals Summary 31

Currency Codes 42

Capital Market Ratios 42

Equity Ratios 43

Profitability Ratios 43

Cost Ratios 44

Liquidity Ratios 44

Leverage Ratios 45

Efficiency Ratios 45

You can also purchase parts of this report.
Do you want to check out a section wise price list?
Get Price Break-up

Why Buy From US?

RRR
Refine Robust Result (RRR) Framework

What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story

reach
Our Reach Is Unmatched

We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.

Research
Shifting the Research Paradigm

While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.

Insite
More Insights-Better Decisions

With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.

Trust
Transparency and Trust

Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.

support
Round the Clock Support

If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.

Why Client Choose Us?

400000+ Reports in repository
150+ Consulting project a year
100+ Analysts
8000+ Client Queries in 2022